New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVilon vs Vesilute

Vilon vs Vesilute

Side-by-side comparison of key properties, dosing, and research.

Immune SupportAnti-Aging & Longevity
Vilon
Anti-Aging & Longevity
Vesilute
Summary
Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
Half-Life
Very short as a free dipeptide; effects mediated via gene regulation
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ, Oral
SubQ, Oral
Research
Typical Dose
1–2 mg SC daily or 5–10 mg oral daily
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Immune system modulation and restoration
  • Lifespan extension (30–40% in animal studies)
  • T-cell and NK-cell activation
  • Epigenetic anti-aging activity
  • Reduces oxidative stress markers
  • Antioxidant gene upregulation
  • May prevent age-related immune senescence
  • Anti-tumor immune surveillance
  • Supports retinal photoreceptor cell function and survival
  • May slow progression of age-related macular degeneration
  • Reduces retinal cell apoptosis from oxidative stress and aging
  • Anti-aging effects on retinal pigment epithelium
  • Potential support in diabetic retinopathy management
  • Preserves visual acuity with aging
  • Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
Side Effects
  • Excellent safety profile, decades of Russian clinical use
  • Rare: mild injection site reaction
  • Very rare: mild allergic reaction
  • Generally well tolerated
  • Mild injection site reactions
  • No significant ocular adverse events reported at standard doses
Stacks With